AAPL310.66-2.00 (-0.64%) ▼|ABBV254.65-0.11 (-0.04%) ▼|ABT95.84+0.21 (+0.22%) ▲|ACN142.14+5.18 (+3.78%) ▲|ADBE221.54+3.47 (+1.59%) ▲|AMAT554.50-38.29 (-6.46%) ▼|AMD516.11-35.94 (-6.51%) ▼|AMGN368.10+1.66 (+0.45%) ▲|AMT165.25+3.14 (+1.94%) ▲|AMZN245.98+1.82 (+0.75%) ▲|AVGO370.78-3.12 (-0.83%) ▼|AXP349.58-6.45 (-1.81%) ▼|BA231.68-2.86 (-1.22%) ▼|BAC59.86-0.04 (-0.07%) ▼|BKNG181.95+0.92 (+0.51%) ▲|BLK1,009.43-1.78 (-0.18%) ▼|BMY57.97+1.27 (+2.24%) ▲|BNY152.91+2.95 (+1.97%) ▲|BRK-B504.00-2.58 (-0.51%) ▼|C140.77-3.09 (-2.15%) ▼|CAT940.12-29.80 (-3.07%) ▼|CL95.03+1.64 (+1.76%) ▲|CMCSA23.41+0.03 (+0.13%) ▲|COF202.89-3.61 (-1.75%) ▼|COP108.44+4.86 (+4.69%) ▲|COST947.50-2.75 (-0.29%) ▼|CRM169.52+3.87 (+2.34%) ▲|CSCO111.79-2.19 (-1.92%) ▼|CVS104.33+2.25 (+2.20%) ▲|CVX174.01+5.91 (+3.52%) ▲|DE603.61-31.63 (-4.98%) ▼|DHR194.19+0.57 (+0.29%) ▲|DIS97.48+0.07 (+0.07%) ▲|DUK128.22+2.25 (+1.79%) ▲|EMR137.91-3.65 (-2.58%) ▼|FDX312.88+2.95 (+0.95%) ▲|GD374.64-2.24 (-0.59%) ▼|GE366.98-11.70 (-3.09%) ▼|GEV1,077.08-74.96 (-6.51%) ▼|GILD136.36+6.75 (+5.21%) ▲|GM76.03-1.82 (-2.34%) ▼|GOOG363.62-1.28 (-0.35%) ▼|GOOGL367.03+0.57 (+0.16%) ▲|GS1,042.98-12.31 (-1.17%) ▼|HD345.21-5.44 (-1.55%) ▼|HON225.05-6.13 (-2.65%) ▼|IBM306.13+6.61 (+2.21%) ▲|INTC110.39-11.81 (-9.66%) ▼|INTU281.17+9.03 (+3.32%) ▲|ISRG427.30-5.53 (-1.28%) ▼|JNJ267.24+7.91 (+3.05%) ▲|JPM339.22+1.50 (+0.44%) ▲|KO84.05+1.09 (+1.31%) ▲|LIN538.23-2.29 (-0.42%) ▼|LLY1,235.56+35.50 (+2.96%) ▲|LMT535.38-2.62 (-0.49%) ▼|LOW220.90-2.88 (-1.29%) ▼|LRCX326.13-24.07 (-6.87%) ▼|MA531.62-1.48 (-0.28%) ▼|MCD282.21+2.71 (+0.97%) ▲|MDLZ60.22+1.05 (+1.77%) ▲|MDT83.83+0.77 (+0.93%) ▲|META615.58+15.29 (+2.55%) ▲|MMM158.01-1.14 (-0.72%) ▼|MO72.96+1.08 (+1.50%) ▲|MRK128.86+2.08 (+1.64%) ▲|MS222.04-0.06 (-0.03%) ▼|MSFT388.84+2.10 (+0.54%) ▲|MU938.38-46.37 (-4.71%) ▼|NEE88.47+1.03 (+1.18%) ▲|NFLX76.18+0.16 (+0.21%) ▲|NKE43.21-0.13 (-0.30%) ▼|NOW110.73+2.80 (+2.59%) ▲|NVDA196.93+1.38 (+0.71%) ▲|ORCL141.60-2.16 (-1.50%) ▼|PEP144.98+1.69 (+1.18%) ▲|PFE24.07+0.35 (+1.48%) ▲|PG152.75+3.44 (+2.30%) ▲|PLTR134.37+1.83 (+1.38%) ▲|PM187.79+3.03 (+1.64%) ▲|QCOM182.97-3.51 (-1.88%) ▼|RTX200.85-0.52 (-0.26%) ▼|SBUX103.61+1.50 (+1.47%) ▲|SCHW101.93+1.31 (+1.30%) ▲|SO97.29+1.30 (+1.35%) ▲|SPG227.19+2.19 (+0.97%) ▲|T21.09+0.51 (+2.48%) ▲|TMO516.62-0.98 (-0.19%) ▼|TMUS184.73+2.94 (+1.62%) ▲|TSLA402.90-16.87 (-4.02%) ▼|TXN293.30-10.20 (-3.36%) ▼|UBER74.33+1.91 (+2.64%) ▲|UNH428.19+10.20 (+2.44%) ▲|UNP283.12+0.53 (+0.19%) ▲|UPS111.96+1.94 (+1.76%) ▲|USB62.89+0.06 (+0.10%) ▲|V352.20-5.05 (-1.41%) ▼|VZ42.59+0.52 (+1.24%) ▲|WFC87.18-0.27 (-0.31%) ▼|WMT111.54+0.89 (+0.80%) ▲|XOM141.69+5.25 (+3.85%) ▲|AAPL310.66-2.00 (-0.64%) ▼|ABBV254.65-0.11 (-0.04%) ▼|ABT95.84+0.21 (+0.22%) ▲|ACN142.14+5.18 (+3.78%) ▲|ADBE221.54+3.47 (+1.59%) ▲|AMAT554.50-38.29 (-6.46%) ▼|AMD516.11-35.94 (-6.51%) ▼|AMGN368.10+1.66 (+0.45%) ▲|AMT165.25+3.14 (+1.94%) ▲|AMZN245.98+1.82 (+0.75%) ▲|AVGO370.78-3.12 (-0.83%) ▼|AXP349.58-6.45 (-1.81%) ▼|BA231.68-2.86 (-1.22%) ▼|BAC59.86-0.04 (-0.07%) ▼|BKNG181.95+0.92 (+0.51%) ▲|BLK1,009.43-1.78 (-0.18%) ▼|BMY57.97+1.27 (+2.24%) ▲|BNY152.91+2.95 (+1.97%) ▲|BRK-B504.00-2.58 (-0.51%) ▼|C140.77-3.09 (-2.15%) ▼|CAT940.12-29.80 (-3.07%) ▼|CL95.03+1.64 (+1.76%) ▲|CMCSA23.41+0.03 (+0.13%) ▲|COF202.89-3.61 (-1.75%) ▼|COP108.44+4.86 (+4.69%) ▲|COST947.50-2.75 (-0.29%) ▼|CRM169.52+3.87 (+2.34%) ▲|CSCO111.79-2.19 (-1.92%) ▼|CVS104.33+2.25 (+2.20%) ▲|CVX174.01+5.91 (+3.52%) ▲|DE603.61-31.63 (-4.98%) ▼|DHR194.19+0.57 (+0.29%) ▲|DIS97.48+0.07 (+0.07%) ▲|DUK128.22+2.25 (+1.79%) ▲|EMR137.91-3.65 (-2.58%) ▼|FDX312.88+2.95 (+0.95%) ▲|GD374.64-2.24 (-0.59%) ▼|GE366.98-11.70 (-3.09%) ▼|GEV1,077.08-74.96 (-6.51%) ▼|GILD136.36+6.75 (+5.21%) ▲|GM76.03-1.82 (-2.34%) ▼|GOOG363.62-1.28 (-0.35%) ▼|GOOGL367.03+0.57 (+0.16%) ▲|GS1,042.98-12.31 (-1.17%) ▼|HD345.21-5.44 (-1.55%) ▼|HON225.05-6.13 (-2.65%) ▼|IBM306.13+6.61 (+2.21%) ▲|INTC110.39-11.81 (-9.66%) ▼|INTU281.17+9.03 (+3.32%) ▲|ISRG427.30-5.53 (-1.28%) ▼|JNJ267.24+7.91 (+3.05%) ▲|JPM339.22+1.50 (+0.44%) ▲|KO84.05+1.09 (+1.31%) ▲|LIN538.23-2.29 (-0.42%) ▼|LLY1,235.56+35.50 (+2.96%) ▲|LMT535.38-2.62 (-0.49%) ▼|LOW220.90-2.88 (-1.29%) ▼|LRCX326.13-24.07 (-6.87%) ▼|MA531.62-1.48 (-0.28%) ▼|MCD282.21+2.71 (+0.97%) ▲|MDLZ60.22+1.05 (+1.77%) ▲|MDT83.83+0.77 (+0.93%) ▲|META615.58+15.29 (+2.55%) ▲|MMM158.01-1.14 (-0.72%) ▼|MO72.96+1.08 (+1.50%) ▲|MRK128.86+2.08 (+1.64%) ▲|MS222.04-0.06 (-0.03%) ▼|MSFT388.84+2.10 (+0.54%) ▲|MU938.38-46.37 (-4.71%) ▼|NEE88.47+1.03 (+1.18%) ▲|NFLX76.18+0.16 (+0.21%) ▲|NKE43.21-0.13 (-0.30%) ▼|NOW110.73+2.80 (+2.59%) ▲|NVDA196.93+1.38 (+0.71%) ▲|ORCL141.60-2.16 (-1.50%) ▼|PEP144.98+1.69 (+1.18%) ▲|PFE24.07+0.35 (+1.48%) ▲|PG152.75+3.44 (+2.30%) ▲|PLTR134.37+1.83 (+1.38%) ▲|PM187.79+3.03 (+1.64%) ▲|QCOM182.97-3.51 (-1.88%) ▼|RTX200.85-0.52 (-0.26%) ▼|SBUX103.61+1.50 (+1.47%) ▲|SCHW101.93+1.31 (+1.30%) ▲|SO97.29+1.30 (+1.35%) ▲|SPG227.19+2.19 (+0.97%) ▲|T21.09+0.51 (+2.48%) ▲|TMO516.62-0.98 (-0.19%) ▼|TMUS184.73+2.94 (+1.62%) ▲|TSLA402.90-16.87 (-4.02%) ▼|TXN293.30-10.20 (-3.36%) ▼|UBER74.33+1.91 (+2.64%) ▲|UNH428.19+10.20 (+2.44%) ▲|UNP283.12+0.53 (+0.19%) ▲|UPS111.96+1.94 (+1.76%) ▲|USB62.89+0.06 (+0.10%) ▲|V352.20-5.05 (-1.41%) ▼|VZ42.59+0.52 (+1.24%) ▲|WFC87.18-0.27 (-0.31%) ▼|WMT111.54+0.89 (+0.80%) ▲|XOM141.69+5.25 (+3.85%) ▲|
18.9 C
New York
Wednesday, July 8, 2026

Tag: press release

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD).

DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Shelby Dermatology d/b/a Dermatologists of Birmingham Clients Whose Data May Have Been...

NEWTOWN, Pa., June 11, 2025 /PRNewswire/ -- The law firm of Edelson Lechtzin LLP is investigating data privacy claims regarding an incident at Shelby...

Montfort Capital Announces First Quarter 2025 Financial Results and CFO Transition

TORONTO, June 11, 2025 /CNW/ - Montfort Capital Corp. ("Montfort" or the "Company") (TSXV: MONT), today announced financial results for the three months ended...

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

NEW YORK, NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that it has deposited into the Company’s trust account (the “Trust Account”) an aggregate of $874.78 to fund the one-month extension from June 11, 2025 to July 11, 2025. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (Nasdaq: SCLX, “Scilex”), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company’s initial business combination or the date of the liquidation of the Company. Upon the closing of a business combination, the note is convertible, at Scilex’s discretion, into the Company’s Class A ordinary shares at a conversion price of $10.00 per share. Any future drawdowns of the remaining $56,920.74 principal amount available under the convertible promissory note are expected to fund future one-month extensions as necessary to provide additional time for the Company to complete a business combination.

Nura Labs Files Revolutionary Patent: AI-Powered Wallet Solves the $180 Billion Crypto Staking Complexity Crisis

Sheridan, WY, June 11, 2025 (GLOBE NEWSWIRE) -- Breakthrough Nura Wallet technology turns crypto staking from 50-exchange nightmare into simple one-click profit machine

Nura Labs, LLC today filed a game-changing patent that could unlock $180 billion in trapped DeFi value. The Company's breakthrough AI technology transforms impossibly complex crypto staking into automated profit generation through the world's first intelligent wallet.

Patent pending — U.S. Provisional Application No. 63/819,482 protects revolutionary algorithms that automatically optimize staking across hundreds of protocols while users simply hold their crypto in the Nura Wallet.

The $180 Billion Problem Finally Solved

Current crypto staking forces users to become day traders across dozens of platforms simultaneously. This complexity locks out 95% of crypto holders from earning passive income on their assets, leaving massive profits on the table. 

"We just eliminated the biggest barrier in crypto," said the Nura Labs team. "The Nura Wallet embeds institutional-grade AI that acts like a personal hedge fund manager, automatically maximizing yields while users sleep."

Patent-Protected Technology Advantage

The 37-claim patent covers three breakthrough innovations:

Protocol-Specific AI Models that understand each DeFi protocol's unique mechanics

Predictive Yield Optimization that forecasts market scenarios for maximum returns

Autonomous Cross-Protocol Management that seamlessly handles complex multi-chain operations

Explosive Performance Results

Real testing delivers game-changing results:

23% higher staking yields vs manual management

67% lower transaction costs through intelligent execution

89% less time required for portfolio optimization

2x better risk-adjusted returns through AI diversification

Massive Market Opportunity

With the DeFi market growing 300% annually and less than 10% user penetration due to complexity, Nura Labs is positioned to capture enormous market share through patent-protected technology that makes institutional-grade staking accessible to everyone.

Multiple Revenue Streams

The patent enables lucrative business opportunities:

● Technology licensing to major crypto platforms

● Direct Nura Wallet operations targeting millions of users

● Strategic partnerships with top DeFi protocols

Aggressive Growth Timeline

Q3 2025: Beta launch and strategic partnerships

Q4 2025: Major protocol integrations

Q1 2026: Public launch capturing mainstream market

Q2 2026: International expansion and institutional features

Investment Catalyst

This patent filing creates a defensible competitive moat around the most valuable innovation in DeFi infrastructure. Nura Labs seeks strategic investors and partners to capitalize on this massive market opportunity. 

"We've built the technology that finally makes crypto work for everyone," continued the team. "This patent protects our path to becoming the dominant wallet in the fastest-growing sector of finance."

Contact Information

Corporate Development: investors@nura.gg

Strategic Partnerships: partnerships@nura.gg

Media Inquiries: media@nura.gg

Nura Labs, LLC

30 N Gould St, STE R, Sheridan, WY 82801

Website: https://nura.gg/

Legal Notice

Patent pending — U.S. Provisional Application No. 63/819,482, filed on 06/06/25. Cryptocurrency investments involve substantial risk. Investment opportunities limited to accredited investors.

Disclaimer: The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities.

Martello Reports Financial Results for the Fourth Quarter and 2025 Fiscal Year

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN...

Currency Exchange International Reports Second Quarter 2025 Results

TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- Currency Exchange International, Corp. (the “Group” or “CXI”) (TSX: CXI; OTCQX: CURN), today reported net income of $1.98 million for the second quarter of 2025, 291% higher than the prior year (all figures are in U.S. dollars except where otherwise indicated). This 2025 reported net income reflected $2.7 million net income from continuing operations and a net loss of $0.7 million from Exchange Bank of Canada, the Company’s Canadian subsidiary which was classified as discontinued operations effective the second quarter of 2025. These results include restructuring charges of $0.2 million, pre-tax, related to discontinued operations in Canada and certain one-time charges of $0.1 million, pre-tax. Excluding these items, the Group’s adjusted net income1 increased by 18% compared to the prior year and adjusted diluted earnings per share1 (“EPS”) was 24% higher than the prior year. The completed condensed interim consolidated financial statements and management’s discussion and analysis (“MD&A”) can be found on the Group’s SEDAR profile at www.sedarplus.ca.

CPKC announces C$1.4 billion debt offering

The shelf prospectus supplement, the corresponding base shelf prospectus and any amendment to the documents is accessible through SEDAR+ CALGARY, AB, June 11, 2025 /PRNewswire/...

MacKenzie Realty Capital Completes The Refinancing of Loan for the Main Street West Property

MacKenzie Realty Capital Completes The Refinancing of Loan for the Main Street West Property

Community Healthcare Trust Releases 2024 Corporate Sustainability Report

FRANKLIN, Tenn., June 11, 2025 /PRNewswire/ -- Community Healthcare Trust Incorporated (NYSE: CHCT) (the "Company") today announced the release of its second Corporate Sustainability...

MediPharm Announces Complete Dismissal of Dissident Court Proceeding Related to Annual and Special Meeting

Ontario Superior Court of Justice fully dismisses application by dissident shareholder Apollo against MediPharm Labs.

New Providence Acquisition Corp. III Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing June 16, 2025

Palm Beach, FL, June 11, 2025 (GLOBE NEWSWIRE) -- New Providence Acquisition Corp. III (Nasdaq: NPACU) (the “Company”) announced today that, commencing June 16, 2025, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The Class A ordinary shares and warrants that are separated will trade on the Nasdaq Global Market under the symbols “NPAC” and “NPACW,” respectively. Those units not separated will continue to trade on the Nasdaq Global Market under the symbol “NPACU.”

Inflection Point Acquisition Corp. III Announces the Separate Trading of its Class A Ordinary Shares and Rights, Commencing on or about June 16, 2025

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Inflection Point Acquisition Corp. III (Nasdaq: IPCXU) (the “Company”) announced that holders of the units sold in the Company’s initial public offering of 25,300,000 units, which includes 3,300,000 units issued pursuant to the exercise by the underwriters of their overallotment option, completed on April 28, 2025 (the “Offering”) may elect to separately trade the Class A ordinary shares and rights included in the units commencing on or about June 16, 2025. Any units not separated will continue to trade on The Nasdaq Global Market under the symbol “IPCXU”, and each of the Class A ordinary shares and rights will separately trade on The Nasdaq Global Market under the symbols “IPCX” and “IPCXR,” respectively. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into Class A ordinary shares and rights.

Renée James will join Portland General Electric board of directors, effective June 11, 2025

PORTLAND, Ore., June 11, 2025 /PRNewswire/ -- Renée James has been appointed to the Portland General Electric (NYSE:POR) ("PGE" or the "Company") board of...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPress release